Serina Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Serina Therapeutics, Inc. on May 22, 2025. The filing reports corporate governance changes, specifically the appointment and departure of Board members, and a technical correction to the company's Certificate of Designations for Series A Convertible Preferred Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
- Board Appointment: Dr. Stephen Brannan was appointed to the Board of Directors and the Compensation Committee, effective May 22, 2025. He brings expertise in neuroscience drug development, having previously served as Chief Medical Officer at Karuna Therapeutics.
- Board Departure: Remy Gross departed the Board of Directors effective May 22, 2025. The departure was not due to any disagreement with the Company.
- Corporate Governance Correction: The Company filed a Certificate of Correction to the Certificate of Designations for Series A Convertible Preferred Stock. This amendment clarifies that the conversion price of $5.18 per share is subject to adjustment pursuant to Section 9(b) of the Certificate, an omission in the original filing.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding future performance. The press release attached as Exhibit 99.1 is furnished under Regulation FD and is not incorporated by reference into registration statements. No specific risks or contingencies are detailed in this report beyond the standard disclosures regarding the Board changes.
Key Facts for Investor Verification
- Verify the full text of the Certificate of Correction (Exhibit 3.1) to confirm the specific voting rights and conversion adjustments for Series A Preferred Stock.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Brannan's appointment and the Company's strategic direction.
- Confirm the effective date of Remy Gross's departure and ensure no undisclosed disagreements exist, as stated in the filing.